Antiviral actions of flavanoid-derived compounds on dengue virus type-2

Abstract

Dengue viruses, mosquito-borne members of the Flaviviridae family, are the causative agents of dengue fever and its associated complications, dengue haemorrhagic fever and dengue shock syndrome. To date, more than 2.5 billion people in over 100 countries are at risk of infection, and approximately 20 million infections were reported annually. There is currently no treatment or vaccine available for dengue infection. This study employed a whole-cell organism model or in vitro methods to study the inhibitory property of the flavanoid-derived compounds against DENV2 activity. Results showed that at concentration not exceeding the maximum non-toxic dose (MNTD), these compounds completely prevented DENV2 infection in HepG2 cells as indicated by the absence of cytophatic effects. The in vitro antiviral activity assessed in HepG2 cells employing virus inhibition assay showed high inhibitory activity in a dose dependent manner. At concentration below MNTD, compounds exhibited inhibitory activity against DENV2 with a range of potency strengths of 72% to 100%. The plaque forming unit per ml (pfu/ml) was reduced prominently with a maximum reduction of 98% when the infected HepG2 cells were treated with the highest non-toxic dose of compounds. The highly potent activity of the compounds against DENV2 infection strongly suggests their potential as a lead antiviral agent for dengue.

Isolation and Purification of Antimicrobical Components from Arthopods, Pheretima asperfillm E.Perrier

“…Arthopods Pheretima asperfillm E.Perrier are common and common, and have long been medicine as raw materials are easy to get, included its prescription is also countless. However, it was rare reported for its pharmacodynamic foundation up to now .The searching of small molecules unknown of the insect and arthopods , may be able to get new drug lead compounds and new antibacterial ingredients, [3][4] further study its value from the molecular point of view, the new drug research and development is also very helpful [5][6].…”

Subversion of immunoproteasome subunit expression in dengue virus serotype 2-infected HepG2 cells

“…In this study, LMP2 and LMP7 expression in cells following treatment with antiviral agent YK73 was investigated 5 . The expression of LMP2 following antiviral treatment was found to be comparable to that in untreated cells; YK73-treated DV2-infected cells demonstrated a 1.…”

“…The expression of these two proteins in DV-infected cells, as well as in those expressing DV non-structural proteins, has been found to be dysregulated [3][4] . The present study aimed to investigate the effects of DV2 infection on LMP2 and LMP7 expression in human HepG2 cells using YK73, which has been shown to act as an antiviral agent against DV 5 .…”

“…Media containing DV2 was aspirated after two hours of incubation at 37°C with humidified 5% CO 2 and cells were rinsed with saline buffer. Culture medium, with or without 5µg/ml of antivirus YK73 5 , was added to the infected cells and further incubated for an additional 48 hours. The antiviral compound YK73 has a maximum non-toxic dose (MNTD) of 25µg/ml and a 90% efficiency in inhibiting viral replication at a concentration of 5µg/ml 5 .…”

<i>In silico</i> antigenic site evaluation and antiviral therapy against dengue serotypes

“…NS3 is responsible for proteolysis of den [gue viral RNA polyprotein as well as carrying out various enzymatic reactions that are mandatory for replication of dengue virus (Luo et al, 2008). Currently there is no antiviral therapy available for Dengue (Muhamad et al, 2010). We assessed the ability of myco -phenolic acid (MPA) and ribavirin (RBV), drug currently used as an immunosuppressive agent, to inhibit dengue virus antigen expression, RNA replication, and virus production (Diamond et al, 2012;Allison et al, 1993;Koff et al, 1983;Conner et al, 1984).…”